Page 58 - TD-3-1

Tumor Discovery Mechanism of Buddleja officinalis against ESCC

Table 2. Potential targets for ESCC inhibition by BO
No. Target Gene symbol Entrez ID
1 Serum albumin ALB 213
2 Carbonic anhydrase 2 CA2 760
3 Thyroid hormone receptor beta THRB 7068
4 Transthyretin TTR 7276
5 Estrogen receptor ESR1 2099
6 Androgen receptor AR 367
7 Peroxisome proliferator- PPARG 5468
activated receptor gamma
8 Cytochrome P450 19A1 CYP19A1 1588
9 Prothrombin F2 2147
10 Wiskott-Aldrich syndrome protein WAS 7454
11 TGF-beta receptor type-1 TGFBR1 7046
12 Tyrosine-protein phosphatase PTPN11 5781
non-receptor type 11
13 Hepatocyte growth factor receptor MET 4233
14 Insulin-like growth factor 1 receptor IGF1 3479
15 Cathepsin D CTSD 1509
16 Glucosylceramidase GBA 2629
17 TGF-beta receptor type-2 TGFBR2 7048
18 Calmodulin CTSK 1513
19 Threonine-protein kinase AKT1 207
20 Basic fibroblast growth factor receptor 1 FGFR1 2260
21 Catenin alpha-1 CTNNA1 1495
22 Fibroblast growth factor receptor 2 FGFR2 2263
23 Leukocyte elastase ELANE 1991
Abbreviations: BO: Buddleja officinalis; ESCC: Esophageal squamous cell carcinoma.

Table 3. Top five core targets with high degree Clinically, high FGFR1 amplification serves as an
independent adverse prognostic factor solely for stage
No. Target Gene Degree I–II ESCC patients, and fibroblast growth factor-2-
30
symbol
1 Serum albumin ALB 17 mediated FGFR1 signaling is involved in the migration
and survival of ESCC cells in vitro. The IGF1 and its
31
2 Insulin-like growth factor 1 receptor IGF1 16 receptor (insulin-like growth factor-1 receptor, IGF-1R)
3 Threonine-protein kinase AKT1 13 promote cell proliferation and inhibit apoptosis. The
32
4 Estrogen receptor ESR1 12 IGF-1R can activate MAPK and PI3K/AKT signaling
5 Basic fibroblast growth factor receptor 1 FGFR1 9 pathways and play an essential role in various cancer
types. 33-36 The AKT is differentially expressed in various
Among the 23 PPI networks of BO-ESCC interaction, cancers and can be involved in various BPs, including
the top five based on degree were ALB, IGF1, AKT1, cell proliferation, apoptosis, transcription, migration,
ESR1, and FGFR1. These proteins were considered invasion, and metastasis. 37-40
as core proteins and could potentially contribute To predict the underlying mechanism of therapeutic
significantly to BO’s therapeutic effect on ESCC. A low effects of BO on ESCC, we performed GO enrichment
ALB level is a predictor of poor survival outcomes in on 23 putative targets. The top 10 targets in BP was
patients with ESCC, and the status of ESR1s in ESCC mainly enriched in organ growth, gland development,
28
is closely associated with poor prognosis and may be and reproductive structure development, indicating
involved in regulating the proliferation of cancer cells. that associated targets were ESR1, AR, TGFBR1, etc. In
29

Volume 3 Issue 1 (2024) 7 https://doi.org/10.36922/td.2312